srpt gene therapy - Search News

Order byBest matchMost fresh

Elevidys, gene therapy

Roche pauses shipments of Elevidys gene therapy outside US

Roche Holding AG said on Tuesday it has paused all shipments of muscular disorder gene therapy Elevidys outside the U.S., echoing a similar decision by U.S. partner Sarepta Therapeutics on Tuesday.

· 18h · on MSN

Sarepta to pause Elevidys gene therapy shipments in U.S.

Zacks.com on MSN · 10h

SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny

· 8h

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Shares of drugmaker Sarepta Therapeutics continued to fall Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of its gene therapy following s...

· 10h

Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.

STAT · 14h

In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

FDA Shuts Down Sarepta Gene Therapy Trials

Digest more

Zacks Investment Research on MSN · 1d

SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its experimental gene therapies. The company confirmed that a 51-year-old, non-ambulant (unable to walk) limb-girdle muscular dystrophy (LGMD) patient died due to acute liver failure (ALF).

· 1d

FDA Places Sarepta's Investigational Gene-Therapy Trials on Hold Following Patient Death

MyChesCo on MSN · 1d

FDA Shuts Down Sarepta Gene Therapy Trials After Three Deaths Linked to Liver Failure

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys

FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due to safety concerns.

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Fintel on MSN11h

Barclays Downgrades Sarepta Therapeutics (SRPT)

Fintel reports that on July 22, 2025, Barclays downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 273.30% Upside As of July 17,